Pharma software, built by practitioners
Mayet was founded by a clinical QA professional and two software entrepreneurs with nearly two decades of experience building and operating SaaS products.
Who We Are
Mayet is a software company specialising exclusively in the pharmaceutical and biotech industry. We build products for the operational problems clinical QA teams face daily: vendor oversight, project tracking, and regulatory alignment. VendorVigilance manages your vendor portfolio across the full study lifecycle. TrialTrack keeps GxP projects on schedule. Our Advisory programme delivers structured consulting for organisations that need to strengthen their processes before adopting software.
- Founded
- 2023, United Kingdom
- Industry
- Pharmaceutical and biotech, exclusively
- Team
- United Kingdom, Spain, Slovenia, Austria
- Regulatory alignment
- ICH E6(R3), 21 CFR Part 11, EudraLex Annex 11, GDPR
How Mayet Started
Tom Lazenby spent his career inside the clinical trial oversight system: monitor, QA manager, QA programme lead. At every organisation he joined, he found himself building or rebuilding systems, but when it came to vendor management and clinical quality processes, there was no true software solution.
Tom partnered with Neyts Zupan and Dejan Murko, software entrepreneurs with nineteen years of shared experience building and operating SaaS products, to change that. Together they founded Mayet in 2023, a software company focused exclusively on pharma and biotech.
VendorVigilance, their first product, launched as the vendor management platform Tom had needed throughout his career. TrialTrack followed, bringing the same domain-driven approach to GxP project management.
Leadership
Tom Lazenby
Founder and CEO
Clinical trials quality assurance professional turned software founder. Over a decade managing vendor audit programmes, quality oversight, and regulatory inspections at GSK, UCL Clinical Trials Unit, and Imperial College London. Single point of accountability for quality oversight across fifty-plus studies at GSK. Every product Mayet builds reflects how clinical QA professionals actually work, because Tom has done the work.
Neyts Zupan
Co-Founder and CTO
Software engineer and technical leader with over twenty years of professional development experience. Co-founded Niteo with Dejan in 2007, a remote-first SaaS company they have built and operated together for nineteen years. Co-founded Pareto Security, a device compliance tool. International conference speaker on Python, web development, and engineering productivity. Responsible for Mayet's technical architecture, security posture, and infrastructure, backed by hands-on experience building a security product.
Dejan Murko
Co-Founder and CPO
Product leader and SaaS entrepreneur. Co-founded Niteo with Neyts in 2007 and has been his business partner for nineteen years, through Niteo, Pareto Security, and now Mayet. Led products that collectively served over 10,000 customers with successful exits. Active SaaS investor with perspective on how software companies are evaluated, acquired, and sustained. His role at Mayet: translate domain expertise and client insights into products that are intuitive, scalable, and solve real problems rather than adding complexity.
Advisors
Mayet's advisory board brings over 120 years of combined experience in pharmaceutical and clinical research.
Dr. Andrew Copestake
Former CEO and CCO with over 30 years in pharma, biotech, and CRO environments.
Rosemarie Corrigan
Executive VP Global Quality with over 30 years in clinical research.
Jo Burmester
Clinical Research Training Consultant with over 30 years in clinical trials.
Chris Shepherd
Pharmaceutical Quality Consultant and former VP R&D Quality at GSK with over 30 years in medicines development.
Validation Partnership
Digital Quality Associates (DQA)
Mayet maintains a strategic partnership with DQA, an independent quality assurance consultancy specialising in healthcare, biotech, and medical devices. DQA provides compliance and validation support to both Mayet and its clients, ensuring that regulatory requirements are addressed from the earliest stages of product development.
Start with a conversation
Book a free one-hour consultation with Tom. No commitment required.